First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer

被引：0
|
作者：
Ohta, Katsuya [1 ,2 ]
Ikenaga, Masakazu [2 ]
Uemura, Mamoru [3 ]
Sakata, Kazuya [2 ,4 ]
Nishimura, Junichi [5 ]
Hata, Taishi [5 ]
Matsuda, Chu [5 ]
Mizushima, Tsunekazu [5 ]
Doki, Yuichiro [5 ]
Mori, Masaki [5 ]
机构：
[1] Colorectal Canc Treatment Grp MCSGO, Multictr Clin Study Grp Osaka, Osaka, Japan
[2] Osaka Univ, Dept Surg Gastroenterol, Suita, Osaka, Japan
[3] Higashiosaka City Gen Hosp, Dept Surg, Higashiosaka, Osaka, Japan
[4] Natl Hosp Org, Osaka Natl Hosp, Dept Surg, Osaka, Japan
[5] Osaka Univ, Dept Surg Gastroenterol, Suita, Osaka, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1549
引用
收藏
页码：216 / 216
页数：1
相关论文
共 50 条
  • [21] A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [22] Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study
    Pinto, Carmine
    Di Fabio, Francesca
    Rosati, Gerardo
    Lolli, Ivan R.
    Ruggeri, Enzo M.
    Ciuffreda, Libero
    Ferrari, Daris
    Lo Re, Giovanni
    Rosti, Giovanni
    Tralongo, Paolo
    Ferrara, Raimondo
    Alabiso, Oscar
    Chiara, Silvana
    Ianniello, Giovanni P.
    Frassoldati, Antonio
    Bilancia, Domenico
    Campanella, Giovanna A.
    Signorelli, Carlo
    Racca, Patrizia
    Benincasa, Elena
    Stroppolo, Maria Elena
    Di Costanzo, Francesco
    [J]. CANCER MEDICINE, 2016, 5 (11): : 3272 - 3281
  • [23] Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer A meta-analysis
    Yang, Ya-Fan
    Wang, Gui-Ying
    He, Jing-Li
    Wu, Feng-Peng
    Zhang, Yan-Ni
    [J]. MEDICINE, 2017, 96 (12)
  • [24] Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort
    Rouyer, Magali
    Francois, Eric
    Cunha, Antonio Sa
    Monnereau, Alain
    Noize, Pernelle
    Robinson, Philip
    Droz-Perroteau, Cecile
    de Sagazan, Alise Le Monies
    Jove, Jeremy
    Lassalle, Regis
    Moore, Nicholas
    Fourrier-Reglat, Annie
    Smith, Denis
    [J]. CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 129 - 139
  • [25] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Tikhonova, Irina A.
    Huxley, Nicola
    Snowsill, Tristan
    Crathorne, Louise
    Varley-Campbell, Jo
    Napier, Mark
    Hoyle, Martin
    [J]. PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
  • [26] CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE
    Souza, P., V
    Zanini, F. E.
    Biglia, L., V
    Kim, H. S.
    Fahham, L.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A875 - A875
  • [27] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Irina A. Tikhonova
    Nicola Huxley
    Tristan Snowsill
    Louise Crathorne
    Jo Varley-Campbell
    Mark Napier
    Martin Hoyle
    [J]. PharmacoEconomics, 2018, 36 : 837 - 851
  • [28] KRAS wild-type status predicts response to cetuximab in metastatic colorectal cancer
    [J]. Nature Clinical Practice Oncology, 2008, 5 (7): : 365 - 365
  • [29] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    [J]. CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
  • [30] Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry
    Chen, Chou-Chen
    Chang, Shih-Ching
    Chang, Yu-Yao
    Lin, Bo-Wen
    Chen, Hong-Hwa
    Hsieh, Yao-Yu
    Hsu, Hung-Chih
    Hsieh, Meng-Che
    Ke, Tao-Wei
    Kuan, Feng-Che
    Wu, Chih-Chien
    Lu, Wei-Chen
    Su, Yu-Li
    Liang, Yi-Hsin
    Chen, Joe-Bin
    Huang, Hsuan-Yuan
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12):
12345